Viela Adds Momentum To Burgeoning NMOSD Market With Pivotal Inebilizumab Results

 
• By Jo Shorthouse

2019 could be the year when three drugs are approved for rare disease neuromyelitis optica, a previously untreatable condition. Viela Bio is the latest to announce positive data from pivotal trials of its monoclonal antibody inebilizumab.

Bike rider
Viela's N-MOmentum trial results look to add treatment options for neuromyelitis optica patients • Source: Shutterstock

More from Clinical Trials

More from R&D